The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 26th 2025
New research confirms hydroxyurea's long-term effectiveness in reducing hospital visits for children with sickle cell anemia, supporting its use as standard treatment.
Walgreens Honors Veterans and Active Duty Military with Veterans Day Discount on November 11
November 1st 2016To celebrate the service and sacrifices of the nation’s military, Walgreens is offering a Veterans Day discount to all veterans, active duty military personnel and their immediate family members.
Read More
Pharmacy professional organizations and stakeholders today released a standardized framework for documenting medication therapy management (MTM) services using SNOMED CT codes — a standard clinical terminology used for the electronic exchange of clinical health information and reporting of clinical quality measures.
Read More
3 Thoughts on the New MassPAT Laws in Massachusetts
October 31st 2016Massachusetts passed a new law requiring practitioners to check MassPAT (the Massachusetts Prescription Awareness Tool) before prescribing narcotics. Whether this will help reduce doctor-shopping will depend on several things.
Read More
QS/1 Offers Pharmacy Therap Interface
October 27th 2016QS/1 is excited to release one of the first pharmacy-to-agency interfaces for Therap, the leading provider in electronic records and documentation in long-term care environments for people with intellectual and developmental disabilities.
Read More
Crisaborole for Atopic Dermatitis
October 27th 2016Atopic Dermatitis (AD) is a chronic, pruritic, relapsing inflammatory skin disease. AD onset is most common between 3 months and 6 months of age, with approximately 60% of patients developing the eruption in the first year of life and 90% by 5 years of age. The majority of affected individuals (70% to 90%) have resolution of disease by adulthood
Read More
Combined Insulin Degludec and Aspart in Insulin-Naïve Patients
October 27th 2016Patients with type 2 diabetes eventually need insulin therapy as their disease progresses. The American Diabetes Association recommends basal-only therapy initially, with the addition of bolus meal-time insulin as needed. However, recent research supports starting patients on combined basal-bolus regimens to control blood sugar regardless of added hypoglycemia risk.
Read More